Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current pharmaceutical design

• Publication date

  2009-07-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/138161209788957438PMID 19689330
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• S‐ketamine and GABA‐A‐receptor interaction in humans: an exploratory study with I‐123‐iomazenil SPECT

  2008cited by this paper
• Type 2 transglutaminase in neurodegenerative diseases: the mitochondrial connection.

  2008cited by this paper
• The application of NMR spectroscopy for the study of heart failure.

  2008cited by this paper
• Initial phase 2 trial of a nicotinic agonist in schizophrenia.

  2008cited by this paper
• Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy—a [123I]CNS-1261 SPET study

  2008cited by this paper
• Neuroactive steroids as endogenous modulators of anxiety.

  2008cited by this paper
• Negative Correlation between Brain Glutathione Level and Negative Symptoms in Schizophrenia: A 3T 1H-MRS Study

  2008cited by this paper
• Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia.

  2008cited by this paper
• Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.

  2008cited by this paper
• The neuronal pathology of schizophrenia: molecules and mechanisms.

  2007cited by this paper
• Acute S-ketamine application does not alter cerebral [18F]altanserin binding: a pilot PET study in humans

  2007cited by this paper
• Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia

  2007cited by this paper
• Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

  2007cited by this paper
• Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review

  2007cited by this paper
• Psychopathological consequences of ketamine

  2006cited by this paper
• Psychological effects of ketamine in healthy volunteers

  2006cited by this paper
• Brain volume changes in the first year of illness and 5-year outcome of schizophrenia

  2006cited by this paper
• Ketamine displaces the novel NMDA receptor SPET probe [(123)I]CNS-1261 in humans in vivo.

  2006cited by this paper
• First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients

  2006cited by this paper
• Glutamate-based therapeutic approaches: inhibitors of glycine transport.

  2006cited by this paper
• What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update

  2006cited by this paper
• Cortical inhibitory neurons and schizophrenia

  2005cited by this paper
• Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study.

  2005cited by this paper
• Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo.

  2005cited by this paper
• The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine’s actions?

  2005cited by this paper
• Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

  2005cited by this paper
• Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function.

  2005cited by this paper
• Cortical glutamate–dopamine interaction and ketamine-induced psychotic symptoms in man

  2005cited by this paper
• GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon

  2005cited by this paper
• Altered prefrontal dopaminergic function in chronic recreational ketamine users.

  2005cited by this paper
• The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS).

  2005cited by this paper
• NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI.

  2005cited by this paper
• Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study.

  2005cited by this paper
• Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: an fMRI study.

  2005cited by this paper
• Subanesthetic Ketamine Does Not Affect 11C-Flumazenil Binding in Humans

  2005cited by this paper
• Duration of untreated psychosis vs. N-acetylaspartate and choline in first episode schizophrenia: a 1H magnetic resonance spectroscopy study at 4.0 Tesla.

  2004cited by this paper
• Calcium binding protein markers of GABA deficits in schizophrenia--postmortem studies and animal models.

  2004cited by this paper
• 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia.

  2004cited by this paper
• Acute Ketamine Administration Alters the Brain Responses to Executive Demands in a Verbal Working Memory Task: an fMRI Study

  2004cited by this paper
• Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia

  2004cited by this paper
• Glutamate as a therapeutic target in psychiatric disorders

  2004cited by this paper
• Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison.

  2003cited by this paper
• Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia

  2003cited by this paper
• In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function.

  2003cited by this paper
• Ketamine and fMRI BOLD signal: Distinguishing between effects mediated by change in blood flow versus change in cognitive state

  2003cited by this paper
• Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment.

  2003cited by this paper
• Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268.

  2003cited by this paper
• Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia.

  2003cited by this paper
• In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia.

  2003cited by this paper
• Half a century of antipsychotics and still a central role for dopamine D2 receptors.

  2003cited by this paper
• Effects of Subanesthetic Doses of Ketamine on Regional Cerebral Blood Flow, Oxygen Consumption, and Blood Volume in Humans

  2003cited by this paper
• Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study

  2003cited by this paper
• Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS.

  2003cited by this paper
• Kinetic modelling of [123I]CNS 1261--a potential SPET tracer for the NMDA receptor.

  2003cited by this paper
• NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans

  2002cited by this paper
• Antiepileptic drugs in schizophrenia: a review

  2002cited by this paper
• NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors—implications for models of schizophrenia

  2002cited by this paper
• Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine.

  2002cited by this paper
• Ketamine does not decrease striatal dopamine D2 receptor binding in man

  2002cited by this paper
• Imaging the PCP site of the NMDA ion channel.

  2002cited by this paper
• Neuronal calcium-binding proteins and schizophrenia.

  2002cited by this paper
• Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers.

  2002cited by this paper
• Sequential Regional Cerebral Blood Flow Brain Scans Using PET with H215O Demonstrate Ketamine Actions in CNS Dynamically

  2001cited by this paper
• Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?

  2001cited by this paper
• A Revised Excitotoxic Hypothesis of Schizophrenia: Therapeutic Implications

  2001cited by this paper
• A systems model of altered consciousness: integrating natural and drug-induced psychoses.

  2001cited by this paper
• The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.

  2001cited by this paper
• A review of MRI findings in schizophrenia.

  2001cited by this paper
• Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons.

  2001cited by this paper
• Brain‐derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration

  2000cited by this paper
• Emerging principles of altered neural circuitry in schizophrenia.

  2000cited by this paper
• Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.

  2000cited by this paper
• Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans.

  2000cited by this paper
• Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients

  2000cited by this paper
• Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo

  2000cited by this paper
• NMDA receptor hypofunction model of schizophrenia.

  1999cited by this paper
• Glutamate Modulation of Dopamine Measured in Vivo with Positron Emission Tomography (PET) and 11C-Raclopride in Normal Human Subjects

  1998cited by this paper
• Schizophrenia and anteroventral thalamic nucleus: selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons.

  1998cited by this paper
• Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex

  1997cited by this paper
• Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET).

  1997cited by this paper
• Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG).

  1997cited by this paper
• Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy.

  1997cited by this paper
• Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy.

  1996cited by this paper
• An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients.

  1996cited by this paper
• Glutamate receptor dysfunction and schizophrenia.

  1995cited by this paper
• Ketamine activates psychosis and alters limbic blood flow in schizophrenia

  1995cited by this paper
• Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease.

  1990cited by this paper

• Significance of NMDA receptor-targeting compounds in neuropsychological disorders: An In-depth Review.

  2025cites this paper
• A SPECT-based method for dynamic imaging of the glymphatic system in rats

  2023cites this paper
• Linking proteomic alterations in schizophrenia hippocampus to NMDAr hypofunction in human neurons and oligodendrocytes

  2021cites this paper
• Metabolite abnormalities in psychosis risk: A meta-analysis of proton magnetic resonance spectroscopy studies.

  2020cites this paper
• Brain networks in pharmacological fMRI of NMDA antagonists

  2019cites this paper
• Cerebral glutamate and GABA levels in high-risk of psychosis states: A focused review and meta-analysis of 1H-MRS studies.

  2019cites this paper
• Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis

  2019cites this paper
• Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience

  2019cites this paper
• Positron Emission Tomography (PET) Ligand Development for Ionotropic Glutamate Receptors: Challenges and Opportunities for Radiotracer Targeting N-Methyl-d-aspartate (NMDA), α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA), and Kainate Receptors.

  2018cites this paper
• General and emotion‐specific neural effects of ketamine during emotional memory formation

  2017cites this paper
• Synthesis and Biological Evaluation of Quinoxaline Derivatives for PET Imaging of the NMDA Receptor

  2017cites this paper
• Basic-self disorders beyond schizophrenia : ultra-high-risk states and panic disorder

  2017cites this paper
• Challenges and opportunities for the development of new antipsychotic drugs.

  2017cites this paper
• PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease

  2017cites this paper
• Species-conserved reconfigurations of brain network topology induced by ketamine

  2016cites this paper
• Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs

  2016cites this paper
• Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction.

  2016cites this paper
• Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction

  2016cites this paper
• Preclinical Reproductive and Developmental Toxicity Profile of a Glycine Transporter Type 1 (Glyt1) Inhibitor.

  2016cites this paper
• Neurochemical and Neuroanatomical Plasticity Following Memory Training and Yoga Interventions in Older Adults with Mild Cognitive Impairment

  2016cites this paper
• NMDA receptor antagonism by repetitive MK801 administration induces schizophrenia-like structural changes in the rat brain as revealed by voxel-based morphometry and diffusion tensor imaging.

  2016cites this paper
• Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice.

  2015cites this paper
• In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophrenia.

  2015cites this paper
• Corticotropin releasing hormone and imaging, rethinking the stress axis.

  2015cites this paper
• Increase in glutamate/glutamine concentration in the medial prefrontal cortex during mental imagery: A combined functional mrs and fMRI study

  2015cites this paper
• New N-aryl-N'-(3-(substituted)phenyl)-N'-methylguanidines as leads to potential PET radioligands for imaging the open NMDA receptor.

  2015cites this paper
• Neurobiological basis of motivational deficits in psychopathology.

  2015cites this paper
• N'-3-(Trifluoromethyl)phenyl Derivatives of N-Aryl-N'-methylguanidines as Prospective PET Radioligands for the Open Channel of the N-Methyl-d-aspartate (NMDA) Receptor: Synthesis and Structure-Affinity Relationships.

  2015cites this paper
• Modeling a model: Mouse genetics, 22q11.2 Deletion Syndrome, and disorders of cortical circuit development.

  2015cites this paper
• The psychosis high-risk state: a comprehensive state-of-the-art review.

  2013cites this paper
• Impaired motor cortex responses in non-psychotic first-degree relatives of schizophrenia patients: a cathodal tDCS pilot study.

  2013cites this paper
• Radiosynthesis of carbon-11 and fluorine-18 labelled radiotracers to image the ionotropic and metabotropic glutamate receptors.

  2013cites this paper
• Metabolic changes in the auditory cortex in presbycusis demonstrated by MR spectroscopy.

  2013cites this paper
• Molecular imaging PET and SPECT approaches for improving productivity of antipsychotic drug discovery and development.

  2013cites this paper
• In vivo measurements of glutamate, GABA, and NAAG in schizophrenia.

  2013cites this paper
• Volumetric Changes in the Basal Ganglia After Antipsychotic Monotherapy: A Systematic Review

  2013cites this paper
• Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans

  2013influential citation
• Neurotransmitters, psychotropic drugs and microglia: clinical implications for psychiatry.

  2013cites this paper
• I disturbi cognitivi nella schizofrenia

  2013cites this paper
• The contribution of the brain response to ketamine to understanding the glutamatergic system and its role in human cognition

  2013cites this paper
• WITHDRAWN: Brain structural, neurochemical and neuroinflammatory markers of psychosis onset and relapse: Is there evidence for a psychosis relapse signature?

  2013cites this paper
• Glutamate and psychosis risk.

  2012cites this paper
• Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia.

  2012cites this paper
• Imaging as tool to investigate psychoses and antipsychotics.

  2012cites this paper
• Eicosapentaenoic Acid Interventions in Schizophrenia: Meta-Analysis of Randomized, Placebo-Controlled Studies

  2012cites this paper
• Neuroimaging correlates of 22q11.2 deletion syndrome: implications for schizophrenia research.

  2012cites this paper
• NMDA receptors, cognition and schizophrenia--testing the validity of the NMDA receptor hypofunction hypothesis.

  2012cites this paper
• Public-private partnerships in translational medicine: concepts and practical examples.

  2012cites this paper
• Brain Imaging in Behavioral Neuroscience

  2012cites this paper
• Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment.

  2012cites this paper
• Preliminary studies of (99m)Tc-memantine derivatives for NMDA receptor imaging.

  2012cites this paper
• Drug targets: single-cell transcriptomics hastens unbiased discovery.

  2012cites this paper
• Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease

  2012cites this paper
• The Glutamate Hypothesis of Schizophrenia: Assessment of a Novel Antipsychotic in Zebrafish Larvae

  2012cites this paper
• Translational Neuroimaging for Drug Discovery and Development in Autism Spectrum Disorders: Guidance from Clinical Imaging and Preclinical Research

  2012cites this paper
• Neuroimaging as a Translational Tool in Animal and Human Models of Schizophrenia

  2012cites this paper
• Neuroimaging Modalities: Description, Comparisons, Strengths, and Weaknesses

  2012cites this paper
• Reply to: Hippocampal Glutamate Levels and Striatal Dopamine D2/3 Receptor Occupancy in Subjects at Ultra High Risk of Psychosis

  2011cites this paper
• Synthesis, evaluation and metabolic studies of radiotracers containing a 4-(4-[18F]-fluorobenzyl)piperidin-1-yl moiety for the PET imaging of NR2B NMDA receptors.

  2011cites this paper
• Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia.

  2011cites this paper
• Application of NMR spectroscopy in medicinal chemistry and drug discovery.

  2011cites this paper
• Electroencephalographic Spectral and Coherence Analysis of Ketamine in Rats: Correlation with Behavioral Effects and Pharmacokinetics

  2011cites this paper
• Proteome analyses of cultured astrocytes treated with MK-801 and clozapine: similarities with schizophrenia

  2011cites this paper
• Effectiveness of cannabidiol in reducing ketamine-induced schizophrenia-like behaviour in both male and female rats

  2011cites this paper
• Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?

  2011cites this paper
• Spontaneous recognition in rats : synaptic plasticity and neurodevelopmental challenge

  2011cites this paper
• Translating Glutamate: From Pathophysiology to Treatment

  2011cites this paper
• Serotonin 2A receptor antagonists for treatment of schizophrenia

  2011cites this paper
• Prenatal lipopolysaccharide treatment enhances MK-801-induced psychotomimetic effects in rats.

  2011cites this paper
• UvA-DARE ( Digital Academic Repository ) 22 q 11 Deletion syndrome and neurotransmitter systems in unchallenged and challenged conditions

  2010cites this paper
• 22q11 Deletion syndrome and neurotransmitter systems in unchallenged and challenged conditions

  2010cites this paper
• PET and SPECT imaging of the NMDA receptor system: an overview of radiotracer development.

  2010cites this paper
• Current awareness in human psychopharmacology

  2010cites this paper
• Using NMR approaches to drive the search for new CNS therapeutics.

  2010cites this paper
• Pharmacoscintigraphy: a blazing trail for the evaluation of new drugs and delivery systems.

  2009cites this paper